IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia
This study has been completed.
Sponsor:
Children's Oncology Group
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01057095
First received: January 26, 2010
Last updated: September 30, 2015
Last verified: May 2015
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at gene expression in tissue samples from patients with acute myeloid leukemia.
| Condition | Intervention |
|---|---|
| Leukemia | Genetic: RNA analysis Genetic: gene expression analysis Genetic: reverse transcriptase-polymerase chain reaction Other: laboratory biomarker analysis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Retrospective |
| Official Title: | Mechanisms of PLAGL2-Induced Leukaemogenesis |
Resource links provided by NLM:
Genetics Home Reference related topics:
core binding factor acute myeloid leukemia
cytogenetically normal acute myeloid leukemia
familial acute myeloid leukemia with mutated CEBPA
Genetic and Rare Diseases Information Center resources:
Myeloid Leukemia
Acute Myeloid Leukemia
Acute Non Lymphoblastic Leukemia
U.S. FDA Resources
Further study details as provided by Children's Oncology Group:
Primary Outcome Measures:
- Correlation of high relative expression levels of PLAGL2 and putative PLAGL2 target genes with potential pathogenic relevance
Biospecimen Retention: Samples With DNA
tissue
| Enrollment: | 20 |
| Study Start Date: | January 2010 |
| Study Completion Date: | April 2010 |
| Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
- Screen acute myeloid leukemia (AML) samples to correlate high relative expression levels of PLAGL2 and putative PLAGL2 target genes (implicated in microarray study) with potential pathogenic relevance with respect to AML development.
OUTLINE: Cryopreserved mRNA from diagnostic samples is analyzed for gene expression by reverse transcriptase-PCR.
Eligibility| Ages Eligible for Study: | up to 120 Years (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Diagnosis of acute myeloid leukemia
Criteria
DISEASE CHARACTERISTICS:
-
Diagnosis of acute myeloid leukemia, including inv(16)(p13;q22) abnormalities
- No t(15;17)(q22;q12) or t(8;21)(q22;q22) abnormalities
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01057095
Please refer to this study by its ClinicalTrials.gov identifier: NCT01057095
Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Soheil Meshinchi, MD | Fred Hutchinson Cancer Research Center |
More Information
| Responsible Party: | Children's Oncology Group |
| ClinicalTrials.gov Identifier: | NCT01057095 History of Changes |
| Other Study ID Numbers: |
AAML10B12 COG-AAML10B12 ( Other Identifier: Children's Oncology Group ) CDR0000664240 ( Other Identifier: Clinical Trials.gov ) NCI-2011-02208 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) |
| Study First Received: | January 26, 2010 |
| Last Updated: | September 30, 2015 |
Keywords provided by Children's Oncology Group:
|
adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with del(5q) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia in remission |
recurrent adult acute myeloid leukemia untreated adult acute myeloid leukemia childhood acute myeloid leukemia in remission recurrent childhood acute myeloid leukemia untreated childhood acute myeloid leukemia and other myeloid malignancies |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms by Histologic Type Neoplasms |
ClinicalTrials.gov processed this record on June 22, 2017